Key result
Sertindole is linked to ~1.3% QTc prolongation risk versus other atypical antipsychotics, without affecting mortality.
Why the study?
Regulatory concerns over serious cardiac dysrhythmias and sudden deaths with sertindole prompted comparison of mortality and cardiac events with other atypical antipsychotics in post-marketing use.
Does sertindole increase mortality rates and cardiac dysrhythmias compared to risperidone and olanzapine in patients prescribed atypical antipsychotics?
Comparison
Sertindole vs risperidone and olanzapine
Design
Observational cohort study using prescription-event monitoring
Authors
Loading...
May warrant QTc monitoring with sertindole; leaves open mortality differences in larger cohorts.
Cohort (n=17,004)
Yes
Does sertindole increase mortality rates and cardiac dysrhythmias compared to risperidone and olanzapine in patients prescribed atypical antipsychotics?
Absolute Event Rate: 1.3% vs 0.006%
Sertindole is associated with a 1.3% incidence of QTc prolongation in post-marketing surveillance, though mortality differences compared to other atypical antipsychotics were not statistically significant due to small sample size.
Wilton et al. (2001) conducted a cohort in Patients prescribed atypical antipsychotics (n=17,004). Sertindole vs. Risperidone and olanzapine was evaluated on Prolongation of QTc interval. Sertindole exposure was associated with a 1.3% incidence of QTc prolongation compared to 0.006% in patients on other atypical antipsychotics, with no significant difference in mortality.